Lataa...
Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
Atrasentan is an oral selective endothelin-A receptor antagonist that may inhibit cell proliferation and interfere with angiogenesis during glioma growth. We conducted a dose-finding study to assess atrasentan’s safety and toxicity and to gather preliminary evidence of efficacy. Patients with recurr...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Duke University Press
2008
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2666236/ https://ncbi.nlm.nih.gov/pubmed/18477765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-013 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|